Considering the rarity of most missense variants in both general populations and cancer patients, and the limited statistical significance in case-control studies to classify these variants as pathogenic or benign, Ikegami et al. conducted a high throughput method using a BRCA2-null cell line (DRD1 BRCA2−/−) into which a BRCA2 vector with a barcoded variant and transposase are transfected. This evidence concerns the gene BRCA2 and cancer.